515 related articles for article (PubMed ID: 21268063)
1. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
3. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
4. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
Migas A; Savva N; Mishkova O; Aleinikova OV
Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
[TBL] [Abstract][Full Text] [Related]
5. [Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations].
Harada H
Rinsho Ketsueki; 2007 Jul; 48(7):541-6. PubMed ID: 17695302
[No Abstract] [Full Text] [Related]
6. Familial myelodysplasia and acute myeloid leukaemia--a review.
Owen C; Barnett M; Fitzgibbon J
Br J Haematol; 2008 Jan; 140(2):123-32. PubMed ID: 18173751
[TBL] [Abstract][Full Text] [Related]
7. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
[TBL] [Abstract][Full Text] [Related]
8. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
Harada H; Harada Y
Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
[TBL] [Abstract][Full Text] [Related]
9. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
Steensma DP; Gibbons RJ; Mesa RA; Tefferi A; Higgs DR
Eur J Haematol; 2005 Jan; 74(1):47-53. PubMed ID: 15613106
[TBL] [Abstract][Full Text] [Related]
10. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
Osato M
Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
[TBL] [Abstract][Full Text] [Related]
11. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
[TBL] [Abstract][Full Text] [Related]
12. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
Harada H; Harada Y; Kimura A
Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
[TBL] [Abstract][Full Text] [Related]
13. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
Harada H; Harada Y; Niimi H; Kyo T; Kimura A; Inaba T
Blood; 2004 Mar; 103(6):2316-24. PubMed ID: 14615365
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterisation of a recurrent, semi-cryptic RUNX1 translocation t(7;21) in myelodysplastic syndrome and acute myeloid leukaemia.
Foster N; Paulsson K; Sales M; Cunningham J; Groves M; O'Connor N; Begum S; Stubbs T; McMullan DJ; Griffiths M; Pratt N; Tauro S
Br J Haematol; 2010 Mar; 148(6):938-43. PubMed ID: 20064152
[TBL] [Abstract][Full Text] [Related]
15. A novel pedigree with heterozygous germline RUNX1 mutation causing familial MDS-related AML: can these families serve as a multistep model for leukemic transformation?
Ripperger T; Steinemann D; Göhring G; Finke J; Niemeyer CM; Strahm B; Schlegelberger B
Leukemia; 2009 Jul; 23(7):1364-6. PubMed ID: 19387465
[No Abstract] [Full Text] [Related]
16. Molecular bases of myelodysplastic syndromes: lessons from animal models.
Komeno Y; Kitaura J; Kitamura T
J Cell Physiol; 2009 Jun; 219(3):529-34. PubMed ID: 19259975
[TBL] [Abstract][Full Text] [Related]
17. High frequency of AML1/RUNX1 point mutations in radiation-associated myelodysplastic syndrome around Semipalatinsk nuclear test site.
Zharlyganova D; Harada H; Harada Y; Shinkarev S; Zhumadilov Z; Zhunusova A; Tchaizhunusova NJ; Apsalikov KN; Kemaikin V; Zhumadilov K; Kawano N; Kimura A; Hoshi M
J Radiat Res; 2008 Sep; 49(5):549-55. PubMed ID: 18724045
[TBL] [Abstract][Full Text] [Related]
18. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome.
Chen CY; Lin LI; Tang JL; Ko BS; Tsay W; Chou WC; Yao M; Wu SJ; Tseng MH; Tien HF
Br J Haematol; 2007 Nov; 139(3):405-14. PubMed ID: 17910630
[TBL] [Abstract][Full Text] [Related]
19. Familial platelet disorder with propensity to acute myelogenous leukemia: genetic heterogeneity and progression to leukemia via acquisition of clonal chromosome anomalies.
Minelli A; Maserati E; Rossi G; Bernardo ME; De Stefano P; Cecchini MP; Valli R; Albano V; Pierani P; Leszl A; Sainati L; Lo Curto F; Danesino C; Locatelli F; Pasquali F
Genes Chromosomes Cancer; 2004 Jul; 40(3):165-71. PubMed ID: 15138996
[TBL] [Abstract][Full Text] [Related]
20. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.
Harada H; Harada Y; Tanaka H; Kimura A; Inaba T
Blood; 2003 Jan; 101(2):673-80. PubMed ID: 12393679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]